Garcia, Bruna Martins https://orcid.org/0000-0002-2257-9370
Melchinger, Philipp https://orcid.org/0000-0002-9376-8400
Medeiros, Tania
Hendrix, Sebastian https://orcid.org/0000-0003-2055-9883
Prabhu, Kavan
Corrado, Mauro https://orcid.org/0000-0002-0617-3274
Kingma, Jenina https://orcid.org/0000-0003-2822-5415
Gorbatenko, Andrej
Deshwal, Soni https://orcid.org/0000-0003-0199-8709
Veronese, Matteo
Scorrano, Luca https://orcid.org/0000-0002-8515-8928
Pearce, Erika
Giavalisco, Patrick https://orcid.org/0000-0002-4636-1827
Zelcer, Noam https://orcid.org/0000-0001-6935-7532
Pernas, Lena https://orcid.org/0000-0002-4337-3435
Funding for this research was provided by:
EC | European Research Council (ERC-StG-2019 852457)
Deutsche Forschungsgemeinschaft (Project ID 269925409)
Deutsche Forschungsgemeinschaft (411422114-GRK 2550)
Netherlands Organization for Scientific Research (NWO; 016.176.643)
Netherlands Organization for Scientific Research (M.22.034; GENESIS)
Howard Hughes Medical Institute (N/A)
Article History
Received: 26 February 2024
Revised: 11 September 2024
Accepted: 20 September 2024
First Online: 21 October 2024
Disclosure and competing interests statement
: BMG and LP are inventors on a European patent application (No. EP23171736.4) filed by the Max-Planck-Gesellschaft. The patent application covers the use of GLUL activators or inhibitors to modulate lipid levels. The remaining authors declare no competing interests.